本文選題：長(zhǎng)鏈非編碼RNA + 結(jié)直腸癌��； 參考：《浙江大學(xué)》2016年博士論文

【摘要】：結(jié)直腸癌是世界上最常見(jiàn)的威脅人類(lèi)健康的惡性腫瘤之一。在所有的惡性腫瘤中,結(jié)直腸癌每年的發(fā)病率和死亡率都高居前列。在最近幾年,全世界每年都有超過(guò)60萬(wàn)患者死于結(jié)直腸癌。超過(guò)90%的腫瘤患者死亡是由腫瘤轉(zhuǎn)移引起的。近年來(lái)的研究顯示：惡性腫瘤細(xì)胞發(fā)生上皮間質(zhì)轉(zhuǎn)化(EMT)是惡性腫瘤發(fā)生轉(zhuǎn)移的重要機(jī)制。EMT是指細(xì)胞在內(nèi)部因素和外界環(huán)境的綜合作用下由上皮細(xì)胞表型轉(zhuǎn)變成間質(zhì)細(xì)胞的過(guò)程。通過(guò)發(fā)生上皮間質(zhì)轉(zhuǎn)化,上皮來(lái)源的惡性腫瘤細(xì)胞獲得間質(zhì)細(xì)胞表型,獲得了侵襲和轉(zhuǎn)移的能力。那么惡性腫瘤發(fā)生EMT的分子機(jī)制又是什么呢?之前的大多數(shù)研究都是集中在對(duì)蛋白質(zhì)分子的研究上。然而蛋白質(zhì)分子所對(duì)應(yīng)的mRNA在人類(lèi)轉(zhuǎn)錄組中只占不到20%,超過(guò)80%的轉(zhuǎn)錄組是不能翻譯成蛋白質(zhì)的。這部分轉(zhuǎn)錄組對(duì)應(yīng)的RNA就是非編碼RNA(noncoding RNA, ncRNA)。這其中大部分是長(zhǎng)度超過(guò)200個(gè)核苷酸的長(zhǎng)鏈非編碼RNA (long noncoding RNA, lncRNA), lncRNA在轉(zhuǎn)錄組中占據(jù)了絕大部分,它們必將會(huì)發(fā)揮著不可替代的功能,否則數(shù)目眾多的lncRNA對(duì)細(xì)胞就會(huì)是一種負(fù)擔(dān),與進(jìn)化過(guò)程中生命對(duì)使用物質(zhì)和能量節(jié)約原則相悖。所以lncRNA在調(diào)控結(jié)直腸癌發(fā)生上皮間質(zhì)轉(zhuǎn)化過(guò)程中也很可能發(fā)揮著重要作用。我們選用TGF-p刺激結(jié)直腸癌細(xì)胞來(lái)構(gòu)建誘導(dǎo)EMT發(fā)生的模型。然后將TGF-p處理的結(jié)直腸癌細(xì)胞作為實(shí)驗(yàn)組,將未處理的結(jié)直腸癌細(xì)胞作為對(duì)照組。為了鑒定出參與結(jié)直腸癌發(fā)生上皮間質(zhì)轉(zhuǎn)化過(guò)程中的lncRNA,我們對(duì)兩組細(xì)胞做了轉(zhuǎn)錄組微矩陣芯片分析。從中鑒定出了差異表達(dá)的長(zhǎng)lncRNA LINC01133。 LINC01133在TGF-β誘導(dǎo)EMT過(guò)程中表達(dá)顯著下調(diào)。于是我們選擇LINC01133作為研究對(duì)象來(lái)研究其在結(jié)直腸癌EMT和轉(zhuǎn)移中的作用,并得出了以下結(jié)論：一、LINC01133的表達(dá)受到TGF-β的抑制。得到芯片結(jié)果之后,我們重復(fù)了TGF-β刺激構(gòu)建結(jié)直腸癌細(xì)胞EMT模型試驗(yàn)。并通過(guò)q-RTPCR對(duì)芯片結(jié)果做了驗(yàn)證,證明LINC01133的表水平確實(shí)能被TGF-β下調(diào)。并且當(dāng)阻斷TGF-β受體或者通過(guò)沉默TGF-β通路下游的smad2后,LINC01133的表達(dá)水平又能恢復(fù)。結(jié)果表明LINC01133是受TGF-β抑制的一條長(zhǎng)鏈非編碼RNA。二、LINC01133抑制結(jié)直腸癌細(xì)胞EMT和轉(zhuǎn)移。為了研究長(zhǎng)鏈非編碼RNA LINC01133在結(jié)直腸癌細(xì)胞發(fā)生EMT和轉(zhuǎn)移中的作用。我們使用小干擾RNA在高表達(dá)LINC01133的結(jié)直腸癌細(xì)胞中的敲低LINC01133表達(dá)水平,在低表達(dá)LINC01133的結(jié)直腸癌細(xì)胞HCT116中過(guò)表達(dá)LINC01133。當(dāng)LINC01133被敲低后,結(jié)直腸癌細(xì)胞的遷移侵襲能力增強(qiáng),上皮標(biāo)志物E-cadherin表達(dá)水平下調(diào),間質(zhì)標(biāo)志物Fibronectin、Twist表達(dá)上調(diào)；LINC01133過(guò)表達(dá)后,結(jié)直腸癌細(xì)胞的遷移侵襲能力減弱,上皮標(biāo)志物E-cadherin表達(dá)水平上調(diào),間質(zhì)標(biāo)志物Fibronectin表達(dá)下調(diào)。同時(shí)小鼠尾靜脈注射肺轉(zhuǎn)移模型顯示,LINC01133敲低后結(jié)直腸癌細(xì)胞的轉(zhuǎn)移能力增強(qiáng)。同時(shí)結(jié)直腸癌臨床樣本研究表明LINC01133在腫瘤組織中表達(dá)明顯下調(diào),腫瘤組織中LINC01133表達(dá)水平高的患者遠(yuǎn)處轉(zhuǎn)移率低,生存預(yù)后好,并且腫瘤組織中LINC01133表達(dá)水平與E-cadherin呈正相關(guān),與Vimentin呈負(fù)相關(guān)。以上結(jié)果表明LINC01133可以抑制結(jié)直腸癌發(fā)生EMT和轉(zhuǎn)移。三、LINC01133與SRSF6相結(jié)合并且可能通過(guò)阻斷SRSF6促EMT的作用來(lái)抑制結(jié)直腸癌EMT和轉(zhuǎn)移(1)鑒定LINC01133的結(jié)合蛋白SRSF6。我們通過(guò)改良ChIRP實(shí)驗(yàn)結(jié)合質(zhì)譜鑒定出LINC01133的結(jié)合蛋白SRSF6.并通過(guò)Western Blot實(shí)驗(yàn)用SRSF6的抗體進(jìn)行了驗(yàn)證。此外,又通過(guò)RIP反向驗(yàn)證SRSF6蛋白對(duì)LINC01133的結(jié)合作用。經(jīng)過(guò)正反兩方面的驗(yàn)證,我們確認(rèn)長(zhǎng)鏈非編碼RNA LINC01133 和 SRSF6 蛋白有相互作用。(2)SRSF6促進(jìn)結(jié)直腸癌細(xì)胞發(fā)生EMT和轉(zhuǎn)移。在鑒定出LINC01133的結(jié)合蛋白SRSF6之后,我們又驗(yàn)證了SRSF6對(duì)結(jié)直腸癌的EMT和轉(zhuǎn)移的調(diào)控作用。我們?cè)诟弑磉_(dá)LINC01133的HT29細(xì)胞系、低表達(dá)LINC01133的HCT116細(xì)胞系和不表達(dá)LINC01133 的 SW620細(xì)胞系中利用慢病毒介導(dǎo)的shRNA將S RSF6干擾敲低。我們發(fā)現(xiàn)當(dāng)SRSF6表達(dá)水平敲低以后,結(jié)直腸細(xì)胞的遷移侵襲能力減弱,上皮標(biāo)志物E-cadherin表達(dá)水平上調(diào),間質(zhì)標(biāo)志物Fibronectin、Twist表達(dá)下調(diào)；LINC01133過(guò)表達(dá)后,結(jié)直腸細(xì)胞的遷移侵襲能力減弱,上皮標(biāo)志物E-cadherin表達(dá)水平表達(dá)上調(diào),間質(zhì)標(biāo)志物Vimentin、 Fibronectin等表達(dá)下調(diào)。以上結(jié)果表明SRSF6可以不依賴于LINC01133,單獨(dú)地促進(jìn)結(jié)直腸癌細(xì)胞EMT和轉(zhuǎn)移。(3)LINC01133對(duì)結(jié)直腸癌細(xì)胞EMT和轉(zhuǎn)移的抑制用依賴于SRSF6我們通過(guò)實(shí)驗(yàn)驗(yàn)證LINC01133對(duì)結(jié)直腸癌細(xì)胞EMT過(guò)程的調(diào)控作用是否依賴于SRSF6.當(dāng)SRSF6的表達(dá)被敲低后,LINC01133對(duì)EMT相關(guān)的蛋白標(biāo)志物的調(diào)控以及對(duì)結(jié)直腸癌細(xì)胞遷移能力的調(diào)控作用都減弱了。結(jié)果提示我們長(zhǎng)鏈非編碼RNALINC01133對(duì)結(jié)直腸癌發(fā)生EMT和轉(zhuǎn)移的抑制作用依賴于其與SRSF6結(jié)合和對(duì)SRSF6促EMT功能的阻斷。綜合以上結(jié)果可以得出結(jié)論：長(zhǎng)鏈非編碼RNA LINC01133通過(guò)與SRSF6相互作用來(lái)抑制結(jié)直腸癌EMT和轉(zhuǎn)移。
[Abstract]:Colorectal cancer is one of the most common malignant tumors that threaten human health in the world. In all malignant tumors, the incidence and mortality of colorectal cancer are high in each year. In recent years, more than 600 thousand patients die from colorectal cancer every year in the world. More than 90% of the patients with swollen tumors are caused by tumor metastasis in recent years. Studies have shown that epithelial mesenchymal transformation (EMT) is an important mechanism for malignant tumor metastasis,.EMT is the process of cell transformation from epithelial cell phenotype to interstitial cell under the combined action of internal and external environment. The cell phenotype has the ability to invasion and metastasis. What is the molecular mechanism of EMT in malignant tumors? Most of the previous studies focus on the study of protein molecules. However, protein molecules correspond to only less than 20% of the mRNA in human transcripts, and more than 80% of the transcriptional groups cannot be translated into protein. Qualitative. The RNA of this part of the transcriptome is the non coded RNA (noncoding RNA, ncRNA). Most of them are long chain non coded RNA (long noncoding RNA, lncRNA) over 200 nucleotides, lncRNA in the transcriptional group, and they will certainly have an unreplaceable function, otherwise a large number of lncRNA pairs The cell will be a burden, which is contrary to the principle of the use of material and energy conservation in the process of evolution. So lncRNA is also likely to play an important role in regulating the epithelial mesenchymal transition in colorectal cancer. We use TGF-p to stimulate colorectal cancer cells to construct a model to induce the occurrence of EMT. Then, the treatment of TGF-p is made straight. In order to identify the lncRNA in the process of epithelial mesenchymal transition in colorectal cancer, we made a microarray microarray analysis of the two groups of cells in order to identify the process of epithelial mesenchymal transition in colorectal cancer. We identified the differential expression of long lncRNA LINC01133. LINC01133 in the TGF- beta induced EMT process. We chose LINC01133 as a study object to study its role in the EMT and metastasis of colorectal cancer, and we concluded that the expression of LINC01133 was inhibited by TGF- beta. After the results of the chip, we repeated the TGF- beta stimulation to construct the EMT model test of colorectal cancer cells and through q-RTPCR The results of the chip proved that the surface level of LINC01133 can be downregulated by TGF- beta. And the expression level of LINC01133 can be recovered after blocking the TGF- beta receptor or through the Smad2 downstream of the silent TGF- beta pathway. The result indicates that LINC01133 is a long chain non coding RNA. two controlled by TGF- beta, and LINC01133 inhibits colorectal cancer cell EMT. To study the role of long chain non coding RNA LINC01133 in EMT and metastasis of colorectal cancer cells. We use small interfering RNA in the low LINC01133 expression level in colorectal cancer cells with high expression of LINC01133, and overexpress LINC01133. in the colorectal cancer cell HCT116 with low expression of LINC01133 when LINC01133 is knocked down, The metastasis and invasion ability of colorectal cancer cells increased, the expression level of epithelial markers E-cadherin was down, the expression of interstitial markers Fibronectin and Twist were up regulated. After LINC01133 overexpression, the migration and invasion ability of colorectal cancer cells weakened, the expression level of E-cadherin in epithelial markers was adjusted, and the expression of interstitial marker Fibronectin was downregulated. At the same time, the expression of interstitial marker Fibronectin was down. The rat tail vein injection model of lung metastasis showed that the metastasis of colorectal cancer cells increased after LINC01133 knockout. At the same time, the colorectal cancer clinical sample study showed that the expression of LINC01133 was obviously downregulated in the tumor tissue. The distant metastasis rate of the patients with high LINC01133 expression level in the tumor tissues was low, the survival prognosis was good, and the tumor tissue was LINC01133 Expression level is positively correlated with E-cadherin and negatively correlated with Vimentin. The above results suggest that LINC01133 can inhibit the occurrence of EMT and metastasis in colorectal cancer. Three, LINC01133 is combined with SRSF6 and may inhibit SRSF6 by blocking the role of SRSF6 to inhibit the EMT and metastasis of colorectal cancer (1) to identify LINC01133 binding protein SRSF6.. The RP experiment combined with mass spectrometry to identify the binding protein SRSF6. of LINC01133 and the antibody of SRSF6 through the Western Blot experiment. In addition, the binding effect of SRSF6 protein on LINC01133 was verified by RIP. Through positive and negative two aspects, we confirmed that the long chain non coded RNA LINC01133 and the SRSF6 protein have interaction. (2) F6 promotes the occurrence of EMT and metastasis in colorectal cancer cells. After identifying the LINC01133 binding protein SRSF6, we also verified the regulatory role of SRSF6 on EMT and metastasis in colorectal cancer. We use the slow disease in the HT29 cell line that expresses the LINC01133, the HCT116 cell lines with low expression of LINC01133 and the SW620 cell line that is not up to the LINC01133. The toxic mediated shRNA interfered with the S RSF6 interference. We found that after the SRSF6 expression level was knocked down, the migration and invasion ability of the colorectal cells was weakened, the expression of E-cadherin in the epithelial markers was up-regulated, the interstitial marker Fibronectin, and the expression of Twist was down regulated. After LINC01133 overexpression, the migration and invasion ability of the colorectal cells weakened and the epithelial marker E was in E. The expression of -cadherin expression was up-regulated and the expression of interstitial markers Vimentin, Fibronectin and so on. The above results showed that SRSF6 could independently promote EMT and metastasis of colorectal cancer cells without LINC01133. (3) the inhibition of LINC01133 on the EMT and metastasis of colorectal cancer cells depends on SRSF6 we have experimentally verified LINC01133 for colorectal cancer. Whether the regulatory role of EMT process in cancer cells depends on the reduction of SRSF6. when the expression of SRSF6 is knocked down, the regulation of EMT related protein markers and the regulation of the migration ability of colorectal cancer cells are weakened. The results suggest that our long chain non coded RNALINC01133 is dependent on the inhibition of EMT and metastasis of colorectal cancer. In combination with SRSF6 and blocking the function of SRSF6 to promote EMT, the above results can be concluded that long chain non coded RNA LINC01133 inhibits colorectal EMT and metastasis by interacting with SRSF6.

【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R735.34

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王漢濤 ,Kraemer M.;隨訪危險(xiǎn)因素分析:復(fù)發(fā)和非復(fù)發(fā)結(jié)直腸癌的比較[J];中國(guó)實(shí)用外科雜志;2001年12期

2 蘇森;患結(jié)直腸癌婦女后代癌癥的危險(xiǎn)性增加[J];中國(guó)腫瘤;2001年06期

3 汪一虹;在確定的法國(guó)人群中年齡<45歲結(jié)直腸癌病人與≥45歲結(jié)直腸癌病人的比較[J];國(guó)外醫(yī)學(xué)(消化系疾病分冊(cè));2002年01期

4 李會(huì)晨;結(jié)直腸癌解剖位置的連續(xù)性右向遷移[J];國(guó)外醫(yī)學(xué).外科學(xué)分冊(cè);2003年03期

5 李志霞;結(jié)直腸癌復(fù)發(fā)及轉(zhuǎn)移的綜合治療[J];中華胃腸外科雜志;2003年06期

6 何建苗,蒲永東,曹志宇,劉衛(wèi)平;老年人結(jié)直腸癌186例的外科治療[J];中華胃腸外科雜志;2003年05期

7 保紅平,方登華,高瑞崗,李奎,張雪松,劉天錫;青年人結(jié)直腸癌臨床病理分析[J];中國(guó)普外基礎(chǔ)與臨床雜志;2004年01期

8 章江;;監(jiān)測(cè)結(jié)直腸癌非常必要[J];國(guó)外醫(yī)學(xué)情報(bào);2004年04期

9 郜文秀,楊艷芳,梁小波,李耀平,李佩珍;細(xì)胞粘附分子變異體在結(jié)直腸癌中的表達(dá)及預(yù)后[J];中國(guó)公共衛(wèi)生;2005年07期

10 Nozawa T. ,Enomoto T. ,Koshida Y. ,M. Kuranami,王志宇;人結(jié)直腸癌黏膜下血小板源性內(nèi)皮細(xì)胞生長(zhǎng)因子特異性增強(qiáng)表達(dá)[J];世界核心醫(yī)學(xué)期刊文摘(胃腸病學(xué)分冊(cè));2005年06期

相關(guān)會(huì)議論文 前10條

1 鄭樹(shù);;結(jié)直腸癌預(yù)后與轉(zhuǎn)移相關(guān)因素分析[A];2005年浙江省腫瘤學(xué)術(shù)會(huì)議全國(guó)大腸癌轉(zhuǎn)移與復(fù)發(fā)的診治研討會(huì)學(xué)術(shù)論文集[C];2005年

2 鄒一峰;吳小劍;蘭平;;結(jié)直腸癌免疫治療新進(jìn)展[A];第十一次全國(guó)中西醫(yī)結(jié)合大腸肛門(mén)病學(xué)術(shù)會(huì)議論文匯編[C];2006年

3 郁寶銘;;結(jié)直腸癌治療的進(jìn)展及其新理念[A];2006年浙江省肛腸外科學(xué)術(shù)年會(huì)論文匯編[C];2006年

4 王錫山;;結(jié)直腸癌治療的困惑之我見(jiàn)[A];第九屆全國(guó)腫瘤轉(zhuǎn)移學(xué)術(shù)大會(huì)暨2011年黑龍江省醫(yī)學(xué)會(huì)腫瘤學(xué)年會(huì)報(bào)告集[C];2011年

5 秦建平;;未病思想中的結(jié)直腸癌預(yù)防[A];貴州省中西醫(yī)結(jié)合學(xué)會(huì)肛腸學(xué)會(huì)第五屆學(xué)術(shù)交流會(huì)暨新技術(shù)新進(jìn)展學(xué)習(xí)班論文匯編[C];2012年

6 高文慶;陳會(huì)林;童蕾;陸松春;;老年梗阻性結(jié)直腸癌診療體會(huì)(附42例報(bào)告)[A];首屆“之江中醫(yī)藥論壇”暨浙江省中醫(yī)藥學(xué)會(huì)2011年學(xué)術(shù)年會(huì)論文集[C];2011年

7 王啟遠(yuǎn);周長(zhǎng)江;高云飛;徐巖;李坤;;血管內(nèi)皮生長(zhǎng)因子與結(jié)直腸癌[A];《中華急診醫(yī)學(xué)雜志》第八屆組稿會(huì)暨急診醫(yī)學(xué)首屆青年論壇論文匯編[C];2009年

8 巴一;;結(jié)直腸癌靶向治療進(jìn)展[A];第三屆中國(guó)腫瘤內(nèi)科大會(huì)教育集暨論文集[C];2009年

9 何超;朱洪波;;結(jié)直腸癌的生物治療[A];2009年浙江省腫瘤外科學(xué)術(shù)年會(huì)暨腫瘤外科規(guī)范化診治學(xué)習(xí)班論文匯編[C];2009年

10 萬(wàn)德森;;進(jìn)一步提高結(jié)直腸癌療效的思考[A];2009年浙江省腫瘤學(xué)術(shù)年會(huì)暨腫瘤診治新進(jìn)展學(xué)習(xí)班論文匯編[C];2009年

相關(guān)重要報(bào)紙文章 前10條

1 中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)主任委員 顧晉;分期不精確 致結(jié)直腸癌過(guò)度治療[N];健康報(bào);2012年

2 本報(bào)記者 賈巖;跨線治療成結(jié)直腸癌最后防線[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

3 本報(bào)記者 賈巖;跨線治療構(gòu)筑結(jié)直腸癌最后防線[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

4 本報(bào)記者 林琳;結(jié)直腸癌：可以治愈的癌癥[N];醫(yī)藥經(jīng)濟(jì)報(bào);2013年

5 記者 張妍　通訊員 熊靜帆 朱品磊;深圳結(jié)直腸癌發(fā)病高于全國(guó)[N];深圳商報(bào);2013年

6 本報(bào)記者 孫剛;預(yù)防結(jié)直腸癌：請(qǐng)管住嘴[N];解放日?qǐng)?bào);2013年

7 上海市中醫(yī)醫(yī)院腫瘤科 侯鳳剛 副主任醫(yī)師;中醫(yī)藥在結(jié)直腸癌治療中的作用和特色[N];上海中醫(yī)藥報(bào);2014年

8 李華虹 孫瑜淼 記者 李麗云 實(shí)習(xí)生 陰浩;專(zhuān)家呼吁：結(jié)直腸癌應(yīng)多學(xué)科規(guī)范化診療[N];科技日?qǐng)?bào);2014年

9 ;降低結(jié)直腸癌復(fù)發(fā)有新療法[N];人民日?qǐng)?bào);2003年

10 韓自力;新化療方案可高效治療結(jié)直腸癌[N];健康報(bào);2007年

相關(guān)博士學(xué)位論文 前10條

1 陳濤;MicroRNA-31/FIH-1調(diào)控關(guān)系在結(jié)直腸癌發(fā)生發(fā)展中的作用及其機(jī)制研究[D];復(fù)旦大學(xué);2014年

2 任翡;MYBL2基因在結(jié)直腸癌的表達(dá)及機(jī)制的初步探討[D];復(fù)旦大學(xué);2014年

3 吳朋;結(jié)直腸癌中microRNA-615基因甲基化及其生物學(xué)特性探究[D];復(fù)旦大學(xué);2014年

4 李澤武;MicroRNA-203靶向ZNF217基因調(diào)控結(jié)直腸癌生物學(xué)行為的研究[D];山東大學(xué);2015年

5 徐興遠(yuǎn);低分子肝素對(duì)結(jié)直腸癌患者預(yù)后的影響及相關(guān)機(jī)制的研究[D];復(fù)旦大學(xué);2014年

6 梁洪亮;miR-454在結(jié)直腸癌中的功能及其作用機(jī)制[D];山東大學(xué);2015年

7 金鵬;MMR蛋白在雌激素致結(jié)腸癌細(xì)胞凋亡中的作用及SEPT9檢測(cè)結(jié)直腸癌的研究[D];第三軍醫(yī)大學(xué);2015年

8 珠珠;云南省Lynch綜合征候選基因標(biāo)志物研究[D];昆明醫(yī)科大學(xué);2014年

9 周智航;SEMA3F通過(guò)下調(diào)ASCL2-CXCR4軸而抑制結(jié)直腸癌轉(zhuǎn)移的分子機(jī)制[D];第三軍醫(yī)大學(xué);2015年

10 王林;MiRNA-300對(duì)結(jié)直腸癌腫瘤侵襲和增殖的影響及其調(diào)控機(jī)制的初步研究[D];第三軍醫(yī)大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 顏斐斐;術(shù)后結(jié)直腸癌患者癌因性疲乏與影響因素的研究[D];南方醫(yī)科大學(xué);2009年

2 李斌;結(jié)直腸癌患者就診延遲分析[D];中南大學(xué);2009年

3 葉建杰;慈溪市結(jié)直腸癌危險(xiǎn)因素病例對(duì)照研究[D];浙江大學(xué);2008年

4 趙波;結(jié)直腸癌危險(xiǎn)因素及臨床流行病學(xué)特征的調(diào)查與分析[D];廣西醫(yī)科大學(xué);2013年

5 崔娟娟;p53和nm23在結(jié)直腸癌中的表達(dá)及其臨床意義[D];河北聯(lián)合大學(xué);2014年

6 宋青芳;正常腸道、癌前病變、結(jié)直腸癌相關(guān)微生物組學(xué)比較分析[D];昆明理工大學(xué);2015年

7 郭秀燕;結(jié)直腸癌術(shù)后生存分析[D];泰山醫(yī)學(xué)院;2014年

8 王靜;TL1A在結(jié)腸炎相關(guān)結(jié)直腸癌動(dòng)物模型中作用的初步探討[D];河北醫(yī)科大學(xué);2015年

9 吳哲;Th17細(xì)胞在TL1A調(diào)控結(jié)腸炎相關(guān)結(jié)直腸癌中作用的初步研究[D];河北醫(yī)科大學(xué);2015年

10 肖華旭;通過(guò)microRNA-155下調(diào)SOCS-1在結(jié)直腸癌的表達(dá)促進(jìn)其轉(zhuǎn)移和侵襲[D];川北醫(yī)學(xué)院;2015年

，

本文編號(hào)：1849414